Genocea Biosciences, Inc.

Equities

GNCAQ

US3724274010

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:56:51 2024-05-10 am EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.00%

2023	Genocea Biosciences, Inc. Went Out of Business	CI
2023	Liquidation Plan Approved for Genocea Biosciences, Inc.	CI

Genocea Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020

February 11, 2021 at 07:31 am EST

Genocea Biosciences, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced operating loss was USD 11.714 million compared to USD 9.862 million a year ago. Net loss was USD 14.985 million compared to USD 9.356 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.34 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to USD 0.34 a year ago. For the full year, operating loss was USD 46.989 million compared to USD 38.989 million a year ago. Net loss was USD 43.714 million compared to USD 38.950 million a year ago. Basic loss per share from continuing operations was USD 0.98 compared to USD 1.89 a year ago. Diluted loss per share from continuing operations was USD 1.11 compared to USD 1.89 a year ago.

Latest news about Genocea Biosciences, Inc.

Genocea Biosciences, Inc. Went Out of Business	23-05-19	CI
Liquidation Plan Approved for Genocea Biosciences, Inc.	23-05-11	CI
First Amended Disclosure Statement Filed by Genocea Biosciences, Inc.	23-03-21	CI
Disclosure Statement Approved for Genocea Biosciences, Inc.	23-03-21	CI
Joint Liquidation Plan and DIsclosure Statement Filed by Genocea Biosciences, Inc.	23-02-09	CI
Motion for Asset Sale Approved for Genocea Biosciences, Inc.	22-09-21	CI
Motion for Asset Sale Approved for Genocea Biosciences, Inc.	22-08-17	CI
Bidding Procedure Approved for Genocea Biosciences, Inc.	22-08-09	CI
Motion for Asset Sale Filed by Genocea Biosciences, Inc.	22-08-04	CI
Genocea Biosciences, Inc. Filed for Bankruptcy	22-07-05	CI
Genocea Biosciences, Inc.(NasdaqCM:GNCA) dropped from S&P TMI Index	22-06-07	CI
Genocea Biosciences, Inc.(NasdaqCM:GNCA) dropped from NASDAQ Composite Index	22-06-02	CI
Genocea Biosciences, Inc. Announces Resignation of Ali Behbahani from Board of Director	22-06-01	CI
US Futures Move Lower Ahead of Durable Goods, Investor Confidence Reports	22-05-25	MT
Top Premarket Gainers	22-05-25	MT
Genocea Biosciences To Wind Down Operations; Shares Fall	22-05-24	MT
Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Top Premarket Decliners	22-04-29	MT
HC Wainwright Downgrades Genocea Biosciences to Neutral From Buy	22-04-29	MT
Stifel Downgrades Genocea Biosciences to Hold From Buy, Adjusts Price Target to $0.16 From $4.70	22-04-29	MT
Genocea Announces Plan to Explore Strategic Alternatives	22-04-28	CI
Transcript : Genocea Biosciences, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022	22-04-11
Baird Adjusts Price Target on Genocea Biosciences to $3 From $8, Keeps Outperform Rating	22-04-11	MT
Wall Street Set for Losses, Surging Treasury Yield Fuels Tech Slump	22-04-11	MT
Top Premarket Gainers	22-04-11	MT

Chart Genocea Biosciences, Inc.

Duration

Period

More charts

Company Profile

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
GENOCEA BIOSCIENCES, INC.	-99.00%	58
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research